Live
- WHOIS database: A new lead generation buzz for 2025
- Retail investors lost Rs 1.8 lakh cr in FY22-FY24 in equity futures and options: SEBI study
- NCLT issues notice to SpiceJet over another unpaid operational debt
- Sub-jr Men's Hockey National: T.N, Punjab, Manipur, Arunachal win on opening day
- Gujarat govt approves Rs 255 crore for road projects in Surat, Rajkot & Gandhinagar civic bodies
- Modi offers 'One Earth' India's expertise in eradicating poverty, bridging digital divide
- Pakistan appoints Lt Gen Asim Malik as new ISI chief
- War of words between ruling, oppn parties over Bengal flood situation continues
- Haaland throwing the ball at Gabriel’s head was a ‘coward’s move’: Arsenal legend Ian Wright
- Labour participation rate hits record 60.1 pc in India’s urban areas, employment rises
Glenmark gets 3 FDA observations
Highlights
Glenmark Pharmaceuticals on Thursday said it has received three observations from the US health regulator for its Pithampur, Indore plant. However, the company said it has responded to the observations issued by the US Food and Drug Administration (USFDA).
New Delhi : Glenmark Pharmaceuticals on Thursday said it has received three observations from the US health regulator for its Pithampur, Indore plant. However, the company said it has responded to the observations issued by the US Food and Drug Administration (USFDA).
"The Indore plant was inspected by USFDA in February 2016 and we received three observations from them which were responded to in March 2016," Glenmark Pharmaceuticals said. Subsequently the company received two product approvals from this plant, it added.
"We have no outstanding items with the USFDA regarding this plant," the Mumbai-based firm said. The Pithampur-based formulations facility manufactures oral solids, semi solids and injectables.
Next Story
ADVERTISEMENT
